Le schede sono disponibili in 中文, English e 日本語; per questa lingua si mostra la versione inglese.
Diabetes & kidneys
Diabetes damages kidneys — but now there are drugs that help
Diabetes is the leading cause of dialysis in many countries — but the last few years brought medicines that protect the kidneys.
- 1Diabetes is the leading cause of new dialysis in the US and many other countries; long-term high glucose damages the kidney filters, usually silently at first.
- 2If you have diabetes, guidelines advise checking eGFR and urine albumin (UACR) at least once a year to catch damage early.
- 3Glucose targets are individual: an HbA1c target anywhere from <6.5% to <8.0% may be appropriate, depending on age, hypoglycaemia risk and other conditions.
- 4SGLT2 inhibitors: recommended for type 2 diabetes with CKD and eGFR ≥20 — they slow kidney decline and protect the heart.
- 5Metformin can be used at eGFR ≥30 (reduce the dose at 30–44); not advised below 30. Medicines must be adjusted as kidney function changes — ask your doctor to review regularly.
With diabetes, ask at your next visit: "Have I had a UACR this year? Am I a candidate for an SGLT2 inhibitor?"
Didascalia (pronta da incollare)
Diabetes is the leading cause of dialysis in many countries — but the last few years brought medicines that protect the kidneys. 1. Diabetes is the leading cause of new dialysis in the US and many other countries; long-term high glucose damages the kidney filters, usually silently at first. 2. If you have diabetes, guidelines advise checking eGFR and urine albumin (UACR) at least once a year to catch damage early. 3. Glucose targets are individual: an HbA1c target anywhere from <6.5% to <8.0% may be appropriate, depending on age, hypoglycaemia risk and other conditions. 4. SGLT2 inhibitors: recommended for type 2 diabetes with CKD and eGFR ≥20 — they slow kidney decline and protect the heart. 5. Metformin can be used at eGFR ≥30 (reduce the dose at 30–44); not advised below 30. Medicines must be adjusted as kidney function changes — ask your doctor to review regularly. With diabetes, ask at your next visit: "Have I had a UACR this year? Am I a candidate for an SGLT2 inhibitor?" Fonti: KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD — Kidney Int 2022;102(5S):S1–S127; USRDS 2023 Annual Data Report — ESRD: Incidence, Prevalence, Patient Characteristics Verificato il: 2026-10-16 Schede e script sono informazione sanitaria generale tratta da linee guida cliniche pubbliche. Non sono consigli medici individuali e non sostituiscono la valutazione di medico, farmacista o dietista. Mantieni fonti e questa nota quando condividi; questa pagina contiene la versione più recente. https://beyondckd.com/it/cards/diabetes-and-kidneys
Script video breve 60 s
Inquadrature e voce fuori campo. Verticale 9:16; sottotitoli nel terzo inferiore. Ogni frase rimanda alle fonti a sinistra.
| s | Schermo | Voce |
|---|---|---|
| 0–5 | Glucose meter + kidney icon | Why does diabetes damage the kidneys — and is there anything that can stop it now? |
| 5–15 | Bar chart: #1 cause of dialysis "diabetes" | In the US and many countries, diabetes is the leading cause of new dialysis. High glucose damages the kidney filters for years, almost without symptoms. |
| 15–25 | Calendar tick "eGFR + UACR" | That is why guidelines advise people with diabetes to check eGFR and urine albumin, UACR, at least once a year. |
| 25–35 | HbA1c scale 6.5–8.0 | Glucose targets are individual. An HbA1c below 6.5 or below 8 may both be right, depending on age, hypoglycaemia risk and other illnesses. |
| 35–47 | Pill "SGLT2i" + kidney & heart shield | Here is the key: SGLT2 inhibitors. For type 2 diabetes with kidney disease and eGFR 20 or above, guidelines recommend them — they slow kidney decline and protect the heart. |
| 47–55 | Metformin + "eGFR ≥30" | Metformin is fine at eGFR 30 and above, reduced at 30 to 44, not advised below 30. When kidney function changes, medicines must change too. |
| 55–60 | Site logo + URL + QR | Ask at your next visit: am I a candidate for an SGLT2 inhibitor? More at Beyond CKD. |
Fonti (ogni punto della scheda vi corrisponde)
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD — Kidney Int 2022;102(5S):S1–S127
- USRDS 2023 Annual Data Report — ESRD: Incidence, Prevalence, Patient Characteristics
Verificato il: 2026-10-16